Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32540902.
- Also identified by DOI 10.1126/science.abc5902 and PMC identifier 7299281.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Neutralizing
- Antibodies, Viral
- Betacoronavirus
- Coronavirus Infections
- Pneumonia, Viral
- Spike Glycoprotein, Coronavirus